An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers

Status:	Recruiting
Conditions:	Cancer, Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	4/3/2019
Start Date:	October 4, 2018
End Date:	July 1, 2023
Contact:	Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,
Email:	Clinical.Trials@bms.com
Phone:	please email

A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (Anti-LAG-3) and Nivolumab in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy as First-Line Treatment in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

The purpose of this study is to determine the efficacy and safety of investigational drug
relatlimab plus nivolumab in combination with chemotherapy in participants with unresectable,
untreated, locally advanced or metastatic gastric or GEJ cancer.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com

Inclusion Criteria:

- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1

- Histologically- or cytologically-confirmed diagnosis of unresectable, locally
advanced, or metastatic gastric cancer or GEJ adenocarcinoma

- No prior treatment with systemic treatment (including HER 2 inhibitors) given as
primary therapy for unresectable, locally advanced, or metastatic GC or GEJ
adenocarcinoma

- Tumor tissue must be provided for biomarker analyses

Exclusion Criteria:

- Participants with HER2 positive status

- Participants with known untreated central nervous system (CNS) metastases

- Uncontrolled or significant cardiovascular disease

Other protocol defined inclusion/exclusion criteria could apply

We found this trial at

sites

Local Institution

Capital Federal, Buenos Aires

from

Capital Federal,